Primary Outcome
In the modified intention-to-treat analysis, 877 (50.8%) of 1725 patients in the GDLM group and 759 (44.1%) of 1723 patients in the placebo group reached the primary outcome (mRS score of 0 or 1 at 90 days; risk difference, 6.79%; 95% CI, 3.46%-10.10%; OR, 1.31; 95% CI, 1.15-1.50; RR, 1.15; 95% CI, 1.08-1.24; 